In domestic pharmaceuticals, DSP designates the Central Nervous System field as one of its focus marketing areas, and offers various treatments such as atypical antipsychotics "LONASEN® " and "LULLAN® ", Parkinson's disease drug "TRERIEF® ", norepinephrine-activating neural function ameliorant "DOPS® ", anti-epileptic drug "EXCEGRAN® ", and serotonin-agonist antianxiety drug "SEDIEL® ". Approximately 230 CNS MRs in the CNS Sales & Marketing Division newly established in April 2011 are developing activities to provide information on these products.
DSP decided to handle a CNS generic drug as part of a plan to strengthen its product lineup in the CNS area. On June 24, 2011, DSP created “Established Products & Chain Pharmacies Groups” dedicated to generic drugs in the CNS area under CNS Sales and Marketing, each under the CNS Higashi-Nippon Region, CNS Capital Region, CNS Kinki-Tokai Region and CNS Nishi-Nippon Region with the aim to promote sales of generic drugs in the CNS area... [PDF] Dainippon Sumitomo Pharma's Press Release -
